Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Blood Specimen Collection 27Surveys and Questionnaires 24Magnetic Resonance Spectroscopy 10Observation 7Flow Cytometry 7Specimen Handling 6Amplified Fragment Length Polymorphism Analysis 6exemestane 5Radiotherapy 5Magnetic Resonance Imaging 5Immunoenzyme Techniques 5Biopsy 5Radiation 4Neoadjuvant Therapy 4Mental Status and Dementia Tests 4Genetic Testing 4Gene Expression Profiling 4Electroporation 4Data Collection 4Bevacizumab 4Trastuzumab 3Tomography, X-Ray Computed 3Tomography, Optical Coherence 3Therapeutics 3Surgical Procedures, Operative 3Sunitinib 3Sorafenib 3Registries 3Radiosurgery 3Psychiatric Rehabilitation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Observational × dinutuximab × Clear all
NCT02693171 2019-08-05

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

United Therapeutics

Terminated
13 enrolled 9 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡